Chronic Hemolysis Clinical Trial
— VITAFLUXOfficial title:
Measurement of Water-soluble Vitamins and Trace Elements Loss With Maintenance Post-dilution Haemodiafiltration Patient
Verified date | May 2022 |
Source | Hospices Civils de Lyon |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
End stage renal disease is a severe pathology in which some toxic waste and an excessive amount of water can accumulate in the human body with life threatening consequences. Maintenance hemodialysis is one of the possible treatment for this disease. Hemodialysis filter the blood through a membrane according to a dialysis bath and so can be able to purify the blood of the toxic waste. Otherwise, since the 1980s, the investigator know that patient in maintenance hemodialysis can have some deficiency in water soluble vitamins and trace elements. Mechanisms of the deficiency are multiple (a decreased of food intake, a diminution of the appetite, digestive malabsorption du to medics and comorbidities and loss in hemodialysis). Impact of this deficiency have an important impact on vital prognosis for these patients. These nutrients are essential for AND synthesis, mechanism of inflammation, cells membranes synthesis, etc. DOPPs study in 2004 have shown a decreased of 16% in the mortality within 4 years with supplemented patients. Also, since this study, international recommendations were wrote in 2009, then in 2020, in order to supplement in vitamins and trace elements patients in maintenance conventional hemodialysis. Despite these recommendations, some supplementary efforts are necessary, especially since online hemodiafiltration, a new process, is widely available and used in particular in Europe. This process combines 2 phenomena, diffusion and convection, through high-flux membranes. This process can remove a large quantity of molecule present in blood and especially the middle-molecule. In return, a more important quantity of water soluble vitamins and oligo-elements could be removed by this technique. Also, the investigator would like to measure this loss of vitamins and trace-elements in patients with maintenance online post-dilution hemodiafiltration process with dialysate sample and blood concentrations measured (usual patient monitoring) during the session.
Status | Completed |
Enrollment | 39 |
Est. completion date | December 10, 2021 |
Est. primary completion date | December 10, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 130 Years |
Eligibility | Inclusion Criteria: - Maintenance hemodialysis more than 3 months - 3 sessions per week during 4 hours - Hemodiafiltration process used with this patient on Lyon Sud Hospital - Flow of the vascular access > 300 mL/min at least - Age > 18 years - Patient able to understand the study's goal Exclusion Criteria: - Active infectious or inflammatory disease - Active malignant disease - Intestinal malabsorptive disease - Polysulfone's dialysis membrane allergy - Patient under guardianship and judicial protection - Pregnant and breastfeeding woman - Opposition to the study |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Lyon Sud | Pierre-Bénite |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of the blood concentrations measured in vitamins and trace elements before and after the hemodialysis session by the post-dilution HDF technique during the half-yearly assessment (usual patient follow-up). | We would like to measure the concentrations of water-soluble vitamins and trace elements in dialysate by collecting 1% of this by Theraflux® device, and compare to the blood concentration collecting during the half-yearly report at the beginning then at the end of one hemodialysis session with online post-dilution hemodiafiltration session. | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01579838 -
An Open Label Study of the Effects of Eculizumab in CD59 Deficiency
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04462614 -
Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA
|
N/A |